Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Givosiran: Timing of Dosing
Standard response letter on the timing of dosing of givosiran in the Phase 1 study.
Standard response letter on the timing of dosing of givosiran in the Phase 1 study.
Patisiran: Concomitant Use with Tafamidis
Standard response letter on patisiran and concomitant use with tafamidis.
Standard response letter on patisiran and concomitant use with tafamidis.
Patisiran: Management of Extravasation
Standard response letter on patisiran and management of extravasation. This medical information response contains information on extravasation prevention guidelines that were provided to patisiran clinical trial sites.
Standard response letter on patisiran and management of extravasation. This medical information response contains information on extravasation prevention guidelines that were provided to patisiran clinical trial sites.
Patisiran: Arthralgia
Standard response letter on patisiran and arthralgia in the APOLLO, APOLLO-B, and HELIOS-A studies.
Standard response letter on patisiran and arthralgia in the APOLLO, APOLLO-B, and HELIOS-A studies.
Patisiran: Use in Patients with Renal Impairment
Standard response letter on patisiran and use in patients with renal impairment. The letter contains information from a post-hoc analysis in patients with ATTR and CKD across the APOLLO, APOLLO-B, Phase 3b Post-OLT, Phase 2 OLE, and Global OLE studies, as well as relevant information from a global safety database.
Standard response letter on patisiran and use in patients with renal impairment. The letter contains information from a post-hoc analysis in patients with ATTR and CKD across the APOLLO, APOLLO-B, Phase 3b Post-OLT, Phase 2 OLE, and Global OLE studies, as well as relevant information from a global safety database.
Givosiran: Use in Patients Without an Identified Porphyria-Related Mutation
Standard response letter on the use of givosiran in patients with AHP without an identified porphyria-related genetic mutation.
Standard response letter on the use of givosiran in patients with AHP without an identified porphyria-related genetic mutation.
Vutrisiran: Analysis of Quality of Life and Physical Function Outcomes in HELIOS-A
Standard response letter on the analysis of quality of life, physical function, and nutritional status outcomes with treatment of vutrisiran in the HELIOS-A study.
Standard response letter on the analysis of quality of life, physical function, and nutritional status outcomes with treatment of vutrisiran in the HELIOS-A study.
